JP6704420B2 - フォンヴィレブランド因子の半減期を改善するための化合物 - Google Patents

フォンヴィレブランド因子の半減期を改善するための化合物 Download PDF

Info

Publication number
JP6704420B2
JP6704420B2 JP2017564947A JP2017564947A JP6704420B2 JP 6704420 B2 JP6704420 B2 JP 6704420B2 JP 2017564947 A JP2017564947 A JP 2017564947A JP 2017564947 A JP2017564947 A JP 2017564947A JP 6704420 B2 JP6704420 B2 JP 6704420B2
Authority
JP
Japan
Prior art keywords
antibody
clec10a
vwf
fviii
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017564947A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510213A (ja
JP2018510213A5 (enExample
Inventor
ミヒャエル・モーゼス
シュテファン・シュルテ
ゲーアハルト・ディックナイテ
ウーヴェ・カリーナ
ザビーネ・ペステル
Original Assignee
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト filed Critical ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト
Publication of JP2018510213A publication Critical patent/JP2018510213A/ja
Publication of JP2018510213A5 publication Critical patent/JP2018510213A5/ja
Application granted granted Critical
Publication of JP6704420B2 publication Critical patent/JP6704420B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017564947A 2015-03-06 2016-03-04 フォンヴィレブランド因子の半減期を改善するための化合物 Expired - Fee Related JP6704420B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15158088 2015-03-06
EP15158088.3 2015-03-06
PCT/EP2016/054650 WO2016142289A1 (en) 2015-03-06 2016-03-04 Compounds for improving the half-life of von willebrand factor

Publications (3)

Publication Number Publication Date
JP2018510213A JP2018510213A (ja) 2018-04-12
JP2018510213A5 JP2018510213A5 (enExample) 2019-04-04
JP6704420B2 true JP6704420B2 (ja) 2020-06-03

Family

ID=52629453

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017564947A Expired - Fee Related JP6704420B2 (ja) 2015-03-06 2016-03-04 フォンヴィレブランド因子の半減期を改善するための化合物

Country Status (12)

Country Link
US (1) US20180043012A1 (enExample)
EP (1) EP3265489B1 (enExample)
JP (1) JP6704420B2 (enExample)
KR (1) KR20170125942A (enExample)
CN (1) CN107428831A (enExample)
AU (1) AU2016231328B2 (enExample)
BR (1) BR112017017852A2 (enExample)
CA (1) CA2978134A1 (enExample)
DK (1) DK3265489T3 (enExample)
ES (1) ES2755449T3 (enExample)
SG (1) SG11201706657PA (enExample)
WO (1) WO2016142289A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4217402A1 (en) * 2020-09-23 2023-08-02 Ablevia biotech GmbH Compound for the prevention or treatment of autoantibody-mediated conditions
EP4251272A4 (en) * 2020-11-24 2024-10-09 Band Therapeutics, LLC COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLEEDING DISORDERS
CN116723863A (zh) * 2020-11-24 2023-09-08 邦德治疗有限公司 用于治疗出血性病症的组合物和方法
CN121991252B (zh) * 2026-04-09 2026-07-17 重庆臻伽亦生物科技有限公司 一种基于优化肽接头的多价cd301融合蛋白、功能化磁珠及其在ctc捕获中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PT1754718E (pt) * 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
CA2465004A1 (en) * 2003-05-19 2004-11-19 National Institute For Biological Standards And Control Composition
JP2005132796A (ja) * 2003-10-31 2005-05-26 Tatsuro Irimura 肉芽組織形成性疾患の治療のための医薬組成物および方法
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
EP2662083A1 (en) * 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
EP2669679A1 (en) * 2012-05-28 2013-12-04 Universitätsklinikum Hamburg-Eppendorf Method for the detection of glycans using polypeptides comprising the CD301 carbohydrate recognition domain
ES2770501T3 (es) * 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
KR20230007555A (ko) * 2013-06-28 2023-01-12 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Also Published As

Publication number Publication date
EP3265489A1 (en) 2018-01-10
WO2016142289A1 (en) 2016-09-15
JP2018510213A (ja) 2018-04-12
CN107428831A (zh) 2017-12-01
KR20170125942A (ko) 2017-11-15
ES2755449T3 (es) 2020-04-22
US20180043012A1 (en) 2018-02-15
SG11201706657PA (en) 2017-09-28
CA2978134A1 (en) 2016-09-15
AU2016231328B2 (en) 2018-07-05
DK3265489T3 (da) 2019-07-15
BR112017017852A2 (pt) 2018-04-10
EP3265489B1 (en) 2019-05-08
AU2016231328A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
Stennicke et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
JP7273487B2 (ja) 第ｖｉｉｉ因子キメラおよびハイブリッドポリペプチドならびにその使用法
US11155601B2 (en) Modified von Willebrand factor having improved half-life
JP6573989B2 (ja) 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド
JP2011504371A (ja) 抗第ｘｉ因子モノクローナル抗体およびその使用方法
EP3212669A1 (en) ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
EP3265489B1 (en) Compounds for improving the half-life of von willebrand factor
JP2020504082A (ja) 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド
JP7252890B2 (ja) 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド
JP6211598B2 (ja) 血友病ａ及び／又はヴォン・ヴィレブランド病を処置するための糖組成物
US20190169307A1 (en) Glycoprotein v inhibitors for use as coagulants
HK1245301B (en) Compounds for improving the half-life of von willebrand factor
HK1245301A1 (en) Compounds for improving the half-life of von willebrand factor
US20220348637A1 (en) Polypeptides for inducing tolerance to factor viii
FVIII A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
WO2021136639A1 (en) Methods for detection of pathogenic antiphospholipid antibodies and for identification of inhibitors

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180904

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20181002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200512

R150 Certificate of patent or registration of utility model

Ref document number: 6704420

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees